C S Bio Co. v. Comerica Bank

District Court, N.D. California·Decided November 10, 2022·No. 3:22-cv-05033·Unknown

Opinion

C S BIO CO., et al., Case No. 22-cv-05033-RS Plaintiffs, v. ORDER GRANTING MOTION TO DISMISS, WITH LEAVE TO AMEND COMERICA BANK, Defendant.

Plaintiffs C S Bio Co. and CCS Management, LLC are related commercial entities (collectively “CS”) who had a long-term banking relationship with defendant Comerica Bank. In the course of that relationship, CS had obtained a number of loans from the bank. In 2019, CS applied to Comerica for a new loan in the amount of $6.6 million to fund the construction of improvements to a property CS owned. CS alleges Comerica thereafter made various representations that the loan had been or would be approved, and would be funded. CS claims it relied on those representations to its detriment by not terminating the project while it still could and by making payments towards the construction costs. CS brought this action after Comerica declined to give final approval and fund the loan. Comerica moves to dismiss, arguing none of CS’s claims are tenable. Because CS has not pleaded sufficient facts to support plausible allegations that Comerica made misrepresentations on The complaint alleges all of the following. In 2019, CS engaged a general contractor in anticipation of making significant improvements to certain commercial real estate it owned in Milpitas. The project was expected to cost approximately $13.6 million, which CS intended to fund with $2 million of its existing resources, a $5 million loan from the Small Business Administration (“SBA”), and a $6.6 million loan from Comerica. CS had been doing business with Comerica since 2013, and had existing loans from the bank on other properties. CS began the loan application process in June of 2019. Comerica advised CS that loan approval would be quicker and easier if CS reduced its existing loan portfolio at the bank. CS therefore replaced one Comerica loan, for approximately $3 million with interest at 3%, with a loan from another lender at 4.25%. In July of 2020, after “extensive negotiations” between CS and Comerica’s Business Banking group, the parties signed a Letter Agreement. The complaint does not attach the Letter Agreement or describe its terms in any detail.1 Around the same time the Letter Agreement was entered, responsibility for the loan application within Comerica was transferred from the Business Banking group (with whom CS had the long-term relationship) to Peter Wentworth and Bill Burke of the bank’s “middle market division.” Wentworth and Burke had no prior experience with CS. The complaint asserts “on information and belief” that Wentworth and Burke are both Vice Presidents at Comerica. Construction at the property had begun in or about June of 2020, with CS funding the initial payments to the contractor itself. Because it could “elect to halt construction by mid- September 2020,” CS asked Wentworth and Burke about the loan status “several times during the summer and fall of 2020.” CS’s CEO, Jason Chang, specifically told the bank he would not continue construction unless the loan was funded, but Comerica told him to go forward, because CS would be reimbursed when the loan went through.

1 Comerica asserts it has located no such agreement in its files. In opposing the motion, CS offers no arguments specifically relying on the alleged letter. During a call on August 27, 2020, Wentworth assured Chang that the loan “was on ‘the 20- yard line’ in term[s] of obtaining approval.” On August 31, 2020, Mr. Wentworth advised Chang that the parties were on “the 15-yard line now and driving.” Two days later, Wentworth told Chang that “once the term sheet was issued, the loan would be approved by Comerica.” Comerica issued the “term sheet” shortly thereafter, and CS returned it signed to Comerica on September 8, 2022. The complaint does not attach the term sheet or describe it in detail, but Comerica has requested judicial notice of the document, to which CS does not object.2 The term sheet began with a “preliminary statement,” in bold:

It does not represent a commitment to loan on the part of Comerica/SBA. If the proposal meets with your approval, it will be subject to other terms and conditions including credit approval by Comerica/SBA, which may include new, additional or other terms and conditions, and also subject to the execution and delivery of all documents and information required by Comerica/SBA in form and substance satisfactory to Comerica/SBA. The term sheet then set out a litany of contingencies and conditions on which loan approval would be dependent. Among these was a “fixed charge coverage ratio” limit with which CS had to comply. Comerica required that ratio, which typically represents a company’s earnings (less capital expenditures and certain other outflows) divided by its fixed expenses, be at least 1.25. The term sheet concluded with a statement, again in bold, that echoed the preliminary statement.

Free access — add to your briefcase to read the full text and ask questions with AI

C S Bio Co. v. Comerica Bank, (N.D. Cal. 2022).

C S Bio Co. v. Comerica Bank (C S Bio Co. v. Comerica Bank) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Conservation Force v. Salazar
646 F.3d 1240 (Ninth Circuit, 2011)
Gary Davis v. Hsbc Bank Nevada, N.A.
691 F.3d 1152 (Ninth Circuit, 2012)
Bily v. Arthur Young & Co.
834 P.2d 745 (California Supreme Court, 1992)
Nymark v. Heart Federal Savings & Loan Ass'n
231 Cal. App. 3d 1089 (California Court of Appeal, 1991)
Jolley v. Chase Home Finance, LLC
213 Cal. App. 4th 872 (California Court of Appeal, 2013)
West v. JPMorgan Chase Bank
214 Cal. App. 4th 780 (California Court of Appeal, 2013)